Loyal
CompanyUnited States
Loyal develops 3 assets, the furthest in veterinary (LOY-001 in lifespan in large dogs). Mostly small molecule acting on IGF1, lipid and ceramide metabolism and INS; based in the United States.
- 3
- Assets
- Furthest stage
- Veterinary
- Raised
- US$204.5m
- 0
- Trials
- 1
- Signal
Pipeline
3Reduces growth hormone and IGF-1 levels to preserve quality of life and extend lifespan.
Veterinary, IGF1, lifespan in large dogs
Improves metabolic health by increasing insulin sensitivity and lowering insulin levels.
Veterinary, Small molecule, Lipid and ceramide metabolism, INS, lifespan in senior dogs
Reduces growth hormone and IGF-1 levels to preserve quality of life and extend lifespan.
Veterinary, Small molecule, Insulin/IGF-1 signalling, IGF1, lifespan in large dogs
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms5
- Funding rounds and grants6
- People19
- Signals4
- Similar companies6
Papers
ITU Tier 1+ #32: Pharmaceuticals (K_pharma)
Zenodo (CERN European Organization for Nuclear Research), 19 May 2026
ITU Tier 1+ #6: Biological Aging (K_aging)
Zenodo (CERN European Organization for Nuclear Research), 19 May 2026